Want to see TSE:VPT full AI Analyst Report?
VPT Stock Chart & Stats
C$0.11
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.11
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.19
Previous CloseN/A
Volume79.10K
Average Volume (3M)106.78K
Market Cap
C$19.28M
Enterprise ValueC$25.07M
Total Cash (Recent Filing)C$55.39K
Total Debt (Recent Filing)C$2.60M
Price to Earnings (P/E)―
Beta-0.74
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding192,777,940
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue AccelerationVery strong top-line acceleration provides a larger base to absorb fixed costs and supports scaling opportunities. Sustained high revenue growth over multiple quarters can validate product-market fit and enable reinvestment in commercialization, improving the odds of eventual operating leverage.
High Gross MarginA materially higher gross margin indicates attractive unit economics in the core device/service mix. Durable mid-to-high gross margins create room for marketing and R&D spend while still enabling a path to profitability if operating expenses stabilize or grow more slowly than revenues.
Improving Cash Burn TrendA meaningful reduction in operating cash burn demonstrates early progress tightening operations or scaling efficiencies. If the trend continues, it reduces near-term financing pressure and makes the business model more durable while management executes on growth and expense discipline.
Bears Say
Stressed Balance SheetDeeply negative equity and increased debt materially constrain financial flexibility and raise solvency risk. Limited asset backing (~$0.47M assets) versus obligations makes the company reliant on external financing, increasing dilution or bankruptcy risk absent sustained cash-flow improvement.
Severe Operating LossesVery large operating losses relative to revenue indicate the business has not yet achieved operating leverage. Persistent heavy losses strain capital, require recurrent funding, and mean that positive revenue trends must materially outpace expense growth to reach sustainable profitability.
Ongoing Cash Burn & Funding RiskConsistent negative operating cash flow and worsening free cash flow create an enduring need for external capital. This raises refinancing and dilution risk, and suggests that reported growth is not yet self-financing, a structural constraint on long-term independence and reinvestment.
VPT FAQ
What was VentriPoint Diagnostics Ltd’s price range in the past 12 months?
VentriPoint Diagnostics Ltd lowest stock price was C$0.08 and its highest was C$0.19 in the past 12 months.
What is VentriPoint Diagnostics Ltd’s market cap?
VentriPoint Diagnostics Ltd’s market cap is C$19.28M.
When is VentriPoint Diagnostics Ltd’s upcoming earnings report date?
VentriPoint Diagnostics Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 13 days.
How were VentriPoint Diagnostics Ltd’s earnings last quarter?
Currently, no data Available
Is VentriPoint Diagnostics Ltd overvalued?
According to Wall Street analysts VentriPoint Diagnostics Ltd’s price is currently Overvalued.
Does VentriPoint Diagnostics Ltd pay dividends?
VentriPoint Diagnostics Ltd does not currently pay dividends.
What is VentriPoint Diagnostics Ltd’s EPS estimate?
VentriPoint Diagnostics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VentriPoint Diagnostics Ltd have?
VentriPoint Diagnostics Ltd has 192,777,940 shares outstanding.
What happened to VentriPoint Diagnostics Ltd’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VentriPoint Diagnostics Ltd?
Currently, no hedge funds are holding shares in TSE:VPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
VentriPoint Diagnostics Ltd
VentriPoint Diagnostics Ltd. is a medical technology company focused on developing and commercializing diagnostic tools worldwide. These innovative solutions are designed to monitor individuals afflicted with cardiovascular disease. At the core of their offerings is the Ventripoint Medical System (VMS), an advanced medical imaging platform. The VMS generates precise three-dimensional models of the heart's chambers, providing crucial volumetric and functional measurements. This system is further enhanced by its VMS+ software, which processes echocardiogram and magnetic resonance imaging (MRI) data to construct these 3D models. The VMS+ software ensures highly reproducible and accurate quantification of heart chamber volumes and ejection fraction. Beyond its current flagship system, VentriPoint Diagnostics is actively expanding its portfolio with a suite of specialized applications. These applications target various cardiac conditions and imaging techniques, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and heart complications stemming from Covid-19. Founded in 2004, the company operates from its headquarters in Toronto, Canada.